Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy [ID2700]
Discontinued
Reference number: GID-TA10574
The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal.
Following an update from the company that market atezolizumab, NICE will not be progressing with the scoping exercise at this stage. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.